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Background: We investigated patterns of failure in patients with locally advanced rectal cancer (LARC) according to
chemoradiotherapy (CRT) timing: pre-operative versus post-operative. Also, patterns of failure, particularly distant
metastasis (DM), were analyzed according to tumor location within the rectum.
Methods: In total, 872 patients with LARC who had undergone concurrent CRT and radical surgery between 2001
and 2007 were analyzed retrospectively. Concurrent CRT was administered pre-operatively (cT3–4) or post-
operatively (pT3–4 or pN+) in 550 (63.1%) and 322 (36.9%) patients, respectively. Median follow-up period was 86
(range, 12–133) months for 673 living patients. Local recurrence (LR) was defined as any disease recurrence within
the pelvis, and any failure outside the pelvis was classified as a DM. Only the first site of recurrence was scored.
Results: In total, 226 (25.9%) patients developed disease recurrence. In the pre-operative CRT group, the incidences
of isolated LR, combined LR and DM, and isolated DM were 17, 21, and 89 patients, respectively. In the post-
operative CRT group, these incidences were 8, 15, and 76 patients, respectively. LR within 2 years constituted 44.7%
and 60.9% of all LRs in the pre-operative and post-operative CRT groups, respectively. Late (> 5 years) LR comprised
13.2% and 4.3% of all LRs in the pre-operative and post-operative CRT groups, respectively. The lung was the most
common DM site (108/249, 43.4%). Lung or para-aortic lymph node metastasis developed more commonly from
low-to-mid rectal tumors while liver metastasis developed more commonly from upper rectal tumors. Lung
metastasis occurred later than liver metastasis (n = 54; 22.6 ± 15.6 vs. 17.4 ± 12.1 months; P = 0.035).
Conclusions: This study showed that LARC patients receiving pre-operative CRT tended to develop late LR more
often than those receiving post-operative CRT. Further extended follow-up than is conventional may be necessary
in LARC patients who are managed with optimized multimodal treatments, and the follow-up strategy may need to
be individualized according to tumor location within the rectum.
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Improvements in adjuvant chemoradiotherapy (CRT)
for patients with locally advanced rectal cancer (LARC)
have involved the sequencing of it, relative to surgical
procedures. After a German randomized study that
demonstrated the superiority of pre-operative CRT over* Correspondence: radiopiakim@hanmail.net
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reproduction in any medium, provided the orpost-operative CRT in local disease control, compliance
with treatment, and toxicity, there has been a paradigm
shift in CRT sequencing in favor of pre-operative CRT
[1]. In parallel to this, improvements in surgical tech-
niques (total mesorectal excision, TME) have lowered
the incidence of local recurrence (LR) of rectal cancer
[2]. Radiotherapy administered before surgery continues
to provide a significant benefit in local disease control,
even with optimized TME [3].
According to the older literature, in which LR rates
were 20–30%, about 80% of LR of rectal cancer presents. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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wide adoption of TME and CRT (pre-operative or post-
operative), LR rates of LARC have been reduced to
~5–10%. Along with this reduction in the LR rate, some
reports indicated a tendency for prolongation of the time
to LR development [4]. This phenomenon has been
reported since general adoption of pre-operative CRT,
but was also shown when post-operative CRT was more
common [5]. However, few studies have compared the
patterns of failure, including time to LR, between LARC
patient groups managed with pre-operative or post-
operative CRT. Regarding distant metastasis (DM) from
LARC, tumor location within the rectum can influence
failure patterns because lymphatic drainage pathways
differ according to vertical subsite in the rectum [6].
Exploring time to DM or DM sites on the grounds of
primary tumor location within the rectum may facilitate
understanding patterns of failure in rectal cancer. This
information will faciliate optimizing or individualizing
follow-up strategies.
In this study, we investigated patterns of failure in pa-
tients with LARC according to CRT timing. Also, patterns




In total, 872 patients with LARC (T3-4 or N+) who had
undergone concurrent CRT and radical surgery between
2001 and 2007 were selected, applying the following inclu-
sion criteria: 1) histologically confirmed adenocarcinoma,
2) no other cancer diagnosed simultaneously or within the
previous 5 years, and 3) no evidence of distant metastasis
before or at the time of surgery. Concurrent CRT was ad-
ministered pre-operatively (cT3–4) or post-operatively
(pT3–4 or pN+) in 550 (63.1%) and 322 (36.9%) patients,
respectively. Since the introduction of pre-operative CRT
at our institution in October 2001, routine treatment for
clinically staged T3–4 rectal cancer located at the mid-
to-low rectum (≤ 9 cm from the anal verge) has gradually
changed from post-operative to pre-operative CRT. During
and after the transition period, upfront surgery with post-
operative CRT was performed routinely for upper (> 9–12
cm) rectal cancer, and for mid-to-low rectal cancer, it was
determined by the preferences of patients or attending
physicians. A tumor was considered to be a rectal cancer if
a proportion of the tumor was located below the peritoneal
reflection or if the lower margin of the tumor was within
12 cm of the anal verge. The study was performed in ac-
cordance with the guidelines of our institutional review
board, which deemed that informed consent was not re-
quired because the study was a retrospective analysis.
All patients underwent pre-treatment workups for clin-
ical staging, including digital rectal examination, completeblood count, liver function tests, serum carcinoembryonic
antigen tests, video colonoscopy, chest radiography, and
computed tomography (CT) scanning of the abdomen and
pelvis with or without transrectal ultrasonography. Add-
itionally, pelvic magnetic resonance imaging (MRI) was
performed in the pre-operative CRT group. 18F-deoxyfluo-
roglucose positron emission tomography was performed as
required. Clinical stage was determined based primarily on
MRI and CT in the pre-operative and post-operative CRT
groups, respectively. Clinically positive lymph node involve-
ment was defined as a lymph node with the smallest dia-
meter of 0.5 cm, observed on CT or MRI. All stages were
determined according to the American Joint Committee on
Cancer Staging System, 6th edition [7].
Treatments
Radiotherapy was delivered to the whole pelvis at a dose
of 45 Gy in 25 fractions, followed by a 5.4 Gy boost in
three fractions within 6 weeks. All patients underwent
CT simulation for three-dimensional conformal plan-
ning, and a three-field treatment plan used a 6-MV pho-
ton posterior-anterior field and 15-MV photon-opposed
lateral beams. The prescription dose was specified at the
isocenter of the planning target volume. The initial radi-
ation field encompassed a volume that included the gross
tumor and mesorectum (pre-operative CRT) or tumor
bed (post-operative CRT), presacral space, the entire sa-
cral hollow, and the regional lymphatics, including the
perirectal, internal iliac, presacral, and distal common iliac
lymphatics. The superior border was placed at L5/S1, and
the inferior border at > 3 cm caudal to the gross tumor or
tumor bed. The boost field included the gross tumor vol-
ume and mesorectum (pre-operative CRT) or tumor bed
(post-operative CRT), with ≥ 2 cm margin in all directions.
Chemotherapy administered concurrently with radio-
therapy was performed according to one of the following
three regimens: 5-fluorouracil and leucovorin, capecitabine,
or capecitabine and irinotecan. The details of the chemo-
therapy regimens were described previously [8]. Patients
underwent radical proctectomy, including high ligation of
the inferior mesenteric vessels and total mesorectal exci-
sion. Lateral node dissection was not performed routinely.
The interval between pre-operative CRT and surgery was
4–8 weeks, and 3–8 weeks between surgery and post-
operative CRT. Post-operative chemotherapy was initiated
3–6 weeks after surgery or post-operative CRT using
one of the following three regimens: 5-fluorouracil and
leucovorin, capecitabine, or an oxaliplatin-based regimen.
Evaluation
All patients underwent standardized follow-up, consisting
of physical examination, complete blood count, liver func-
tion tests, serum carcinoembryonic antigen tests, and chest
radiography every 3 months for the first 2 years, and every






Age (mean, yr) 57.0 ± 10.9 57.8 ± 10.5 0.272
Gender
Male 370 (67.3) 202 (62.7) 0.173
Female 180 (32.7) 120 (37.3)
Histological grade*
Low 516 (94.9) 278 (94.9) 0.986
High 28 (5.1) 15 (5.1)
CEA (ng/mL)
≤ 5.0 370 (67.3) 178 (65.0) 0.508
> 5.0 180 (32.7) 96 (35.0)
Tumor location (cm) †
Low (< 5.0) 203 (36.9) 45 (14.9) < 0.001
Middle (5.0–9.0) 347 (63.1) 143 (47.2)
Upper (> 9.0–12.0) 115 (38.0)
Clinical stage
II 111 (20.2) 77 (23.9) 0.196
III 439 (79.8) 245 (76.1)
Pathological stage
0 84 (15.3) < 0.001
I 145 (26.4)
II 154 (28.0) 88 (27.3)
III 167 (30.4) 234 (72.7)
CRM
Negative 506 (92.0) 290 (90.1) 0.328
Positive 44 (8.0) 32 (9.9)
Abbreviations: CRT = chemoradiotherapy; CEA = carcinoembryonic antigen;
CRM = circumferential resection margin.
*Evaluated with pretreatment diagnostic biopsy specimen. Low = well or
moderately differentiated; high = poorly differentiated, mucinous, or signet
ring cell carcinoma.
†Distance of distal end of tumor from anal verge.
‡t-test, Chi-square test, or Fisher’s exact test.
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months. Colonoscopic examinations were performed 1 year
post-operatively, and then once every 2 years. Recurrence
was determined on clinical, radiological or histological
grounds. Radiological evidence involved serial radiological
examinations showing progressive growth of the mass, in-
cluding abnormally high uptake on 18F-deoxyfluoroglucose
positron emission tomography.
Statistical analyses
Intergroup comparisons were conducted using the chi-
square test, Fisher’s exact test, linear-by-linear association,
or t-test, depending on the nature of the data. LR was
defined as any disease recurrence within the pelvis, and
any failure outside the pelvis was classified as a DM. Only
the first site of recurrence was scored. Disease-free sur-
vival (DFS) was defined as the time interval between CRT
initiation (pre-operative CRT) or surgery (post-operative
CRT) and any type of recurrence. The survival time of
patients remaining free of recurrence was censored. DFS
was estimated using the Kaplan-Meier method, and the
significance of differences was assessed with the log-rank
test. The level of statistical significance was set at P < 0.05;
all reported P-values were two-tailed. Statistical analyses
were performed using the SPSS software (release 14.0;
SPSS Inc., Chicago, IL, USA).
Results
Patients and treatment outcomes
Table 1 lists patient demographics and disease character-
istics. No statistically significant difference was observed
between the two CRT sequence groups in pre-treatment
characteristics, including age, gender, histological grade,
serum carcinoembryonic antigen level and clinical stage,
except for tumor location; even after excluding upper
rectal cancer, significantly more patients with low rectal
cancer were treated initially with pre-operative CRT
rather than up-front surgery (36.9% vs. 23.9%; P = 0.001).
In the pre-operative CRT group, downstaging to ypStage
0–I occurred in 229 (41.7%) patients. Sphincter-sparing
surgery rates were significantly higher in the post-
operative CRT group (88.8%, n = 286 vs. 82.7%, n = 455;
P = 0.015), however, this difference was not found upon
exclusion of patients with upper rectal cancer in the
post-operative CRT group (83.0%, n = 156, vs. 82.7%, n =
455; P = 0.937). The positive circumferential resection
margin (≤ 0.1 cm) rate was not different between the
two CRT groups. This rate was significantly higher in
patients with low rectal tumors (16.9%) compared with
mid (5.7%) or upper (4.3%) tumors (P < 0.001).
Failure patterns according to CRT timing
For the 673 living patients, the median follow-up period
was 86 (range, 12–133) months. In total, 226 (25.9%)patients developed disease recurrence. In pre-operative
CRT group, the incidences of isolated LR, combined LR
and DM, and isolated DM were 17 (13.4%), 21 (16.5%),
and 89 (70.1%) patients, respectively. In the post-
operative CRT group, these incidences were 8 (8.1%), 15
(15.2%), and 76 (76.8%) patients, respectively. In the pre-
operative and post-operative CRT groups, the actuarial
7-year LR rates were 7.4% and 7.2%, respectively (P =
0.803), the DM rates were 16.5% and 24.5%, respectively
(P = 0.004), and the DFS rates were 76.5% and 68.9%, re-
spectively (P = 0.007). Recurrence type (LR vs. DM) did
not differ between the two CRT groups. The lung was
the most common site of DM (108/249, 43.4%) and the
proportions of DM sites did not differ between the
groups (Table 2). Pre-operative CRT seemed to delay LR
more than post-operative CRT, but time to failure was
Table 2 Patterns of failure according to CRT timing
Site of failure Pre-op CRT, n (%) Post-op CRT, n (%) P‡
Type of recurrence LR alone 17 (13.4) 8 (8.1) 0.573
LR with DM 21 (16.5) 15 (15.2)
DM alone 89 (70.1) 76 (76.8)
Total 127 (100) 99 (100)
DM site* Lung 64 (48.1) 44 (37.9) 0.208
Liver 24 (18.0) 30 (25.9)
PAN 27 (20.3) 20 (17.2)
Others† 18 (13.5) 22 (19.0)
Total 133 (100) 116 (100)
Time to failure Pre-op CRT, months Post-op CRT, months P‡
Type of recurrence LR alone 37.2 ± 21.2 35.2 ± 27.4 0.841
LR with DM 25.6 ± 21.3 19.9 ± 13.3 0.372
DM alone 21.2 ± 15.9 19.1 ± 12.1 0.334
Total 24.1 ± 18.3 20.5 ± 14.5 0.112
DM site* Lung 24.3 ± 18.2 20.1 ± 10.7 0.130
Liver 16.5 ± 9.3 18.2 ± 14.1 0.597
PAN 18.8 ± 16.6 19.0 ± 13.5 0.964
Others† 21.5 ± 15.4 18.3 ± 13.9 0.494
Abbreviations: CRT = chemoradiotherapy; LR = local recurrence; DM = distant metastasis; PAN = para-aortic lymph node.
*Some patients had distant metastases occurring at multiple sites.
†Peritoneal seeding, inguinal lymph node, bone, brain, supraclavicular lymph node.
‡Linear-by-linear association or t-test.
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rrences were stratified according to incidence time inter-
vals, LR (alone or with DM) within 2 years constituted
44.7% and 60.9% of all LRs in the pre-operative and
post-operative CRT groups, respectively. Late (> 5 years)
LR (alone or with DM) comprised 13.2% and 4.3% of all
LRs in the pre-operative and post-operative CRT groups,
respectively (Table 3, Figure 1).
For all patients included in the study, time to LR
(alone or with DM; n = 61) was significantly longer than
time to DM (DM alone; n = 165; 28.7 ± 21.3 vs. 20.2 ±
14.3 months; P = 0.005). When this was analyzed separ-
ately according to CRT scheme, a significant difference
was found only in the pre-operative CRT group (LR,
30.8 ± 21.9 vs. DM, 21.2 ± 15.9 months; P = 0.018), not inTable 3 Recurrence proportions at each time interval accordin
LR alone* LR with DM*
Year Pre-op CRT Post-op CRT Pre-op CRT Post-op CR
≤ 2 4 (41.2) 4 (50.0) 13 (61.9) 10 (66.7
> 2–5 10 (47.0) 3 (37.5) 6 (28.6) 5 (33.3
> 5 3 (11.8) 1 (12.5) 2 (9.5)
17 (100) 8 (100) 21 (100) 15 (100
Abbreviations: CRT = chemoradiotherapy; LR = local recurrence; DM = distant metasta
*All P-values by linear-by-linear association were not significant.the post-operative CRT group (LR, 25.3 ± 20.2 vs. DM,
19.1 ± 12.1 months; P = 0.173).
Failure patterns according to tumor location
Patients with upper rectal tumors comprised 13.2%
(115/872) of the total. Their LR/DM ratio was slightly
lower than patients with low-to-mid rectal tumors (not
significant). Lung or para-aortic lymph node metastasis
developed relatively more frequently from low-to-mid
rectal tumors while liver metastasis was more frequent
from upper rectal tumors (P = 0.041; Table 4). Time to
DM was slightly longer in low-to-mid rectal tumors com-
pared with upper rectal tumors (20.7 ± 14.4 vs. 17.9 ± 13.5
months), but the difference was not statistically significant
(P = 0.405); however, a significantly increased time to DMg to CRT timing
DM alone* Total*
T Pre-op CRT Post-op CRT Pre-op CRT Post-op CRT
) 63 (70.8) 56 (73.7) 80 (63.0) 70 (70.7)
) 22 (24.7) 19 (25.0) 38 (29.9) 27 (27.3)
0 4 (4.5) 1 (1.3) 9 (7.1) 2 (2.0)
) 89 (100) 76 (100) 127 (100) 99 (100)
sis.
Figure 1 Proportions (%) of local recurrence (alone or with
distant metastasis) each year according to CRT timing.
Figure 2 Proportions (%) of isolated distant metastasis each
year according to tumor location.
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to-upper rectal tumors (24.2 ± 18.7 vs. 18.3 ± 11.0 months;
P = 0.036) (Figure 2). Among DM sites (in all patients),
lung metastasis (n = 108) occurred later than liver metas-
tasis (n = 54; 22.6 ± 15.6 vs. 17.4 ± 12.1 months; P = 0.035).
Discussion
Late development of LR in patients with rectal cancer has
been reported when pre-operative CRT is performed.
Coco et al. reported that almost one-third (28%) of LR
was detected beyond 5 years with > 9 years follow-up in
83 LARC patients [9]. Ngan et al. reported two among
three LRs occurred after 2 years, with a median 4 years of
follow-up [10]. Moutardier et al. reported that 9 of 10 LRs
occurred after 2 years (4/10 after 5 years) and median time
to LR detection was 39 months after a median follow-up
of 75 months [11]. This late LR development was also
reported after application of post-operative radiotherapy.
Bentzen et al. reported that only patients with Dukes’ C
rectal tumors benefited in terms of local control from
post-operative radiotherapy, and median time to LR was
longer, 34 months after post-operative radiotherapy, com-
pared with 12 months after surgery alone [5].Table 4 Patterns of failure according to tumor location







LR alone 22 (11.3) 2 (8.0) 0.607
LR with DM 33 (16.9) 2 (8.0)
DM alone 140 (71.8) 21 (84.0)
Total 195 (100) 25 (100)
DM site Lung or PAN 117 (81.3) 12 (60.0) 0.041
Liver 27 (18.7) 8 (40.0)
Abbreviations: LR = local recurrence; DM = distant metastasis; PAN = para-aortic
lymph node.
*Linear-by-linear association or chi-square test.In the current study, we compared time to LR directly
between the two CRT groups, both of which received
TME-based surgery during the same time period, and
showed a tendency of later development when CRT was
administered pre-operatively. LR of 13.2% was shown
after 5 years in the pre-operative CRT group, while of
only 4.3% in the post-operative CRT group. LR within 2
years constituted a higher proportion (60.9%) of all LRs
in post-operative CRT than in the pre-operative CRT
group (44.7%). LR development took more time com-
pared with DM, but a significant difference existed only
in the pre-operative CRT group. Collectively, the pre-
operative CRT group tended to develop LR later than
the post-operative CRT group, and this difference was
significant, compared with DM in the pre-operative CRT
group.
Recently, the long-term follow-up (median 11 years)
outcome of the German randomized trial was published
[12]. The 10-year cumulative incidence of LR was still sig-
nificantly lower in the pre-operative CRT arm, as was the
case in a previous report after a median follow-up of 46
months [1]. The cumulative incidences of LR at 5 and 10
years in the intention-to-treat population were 5% and
7.1%, respectively, in the pre-operative CRT arm and 9.7%
and 10.1%, respectively, in the post-operative CRT (P =
0.048 at 10 years). Notably, among seven (12%, 7/60) late
(> 5 years) LR, five (23%, 5/22) occurred in the
pre-operative CRT arm and two (5%, 2/38) in the post-
operative CRT arm. The median time to LR was 15.1
months for the 17 patients without post-operative CRT
(post-operative CRT arm), 18.7 months for the 21 patients
with post-operative CRT, and 30.7 months for the 22
patients after pre-operative CRT (P = 0.05). Compared
with this German trial, the present study had some diffe-
rences. First, compliance with post-operative CRT was
significantly inferior than with pre-operative CRT in the
German study [1], while our study selected retrospectively
only patients who had received CRT, whether pre- or
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cancer were included only in the post-operative CRT
group. Generally, upper rectal cancer, although the de-
finition of location is somewhat variable, including
peritonealization status [6], has shown relatively lower LR
and lower efficacy of pre-operative radiotherapy [13]. The
5-year LR rates for upper and mid-to-low rectal cancer
were 2.6% versus 9.8% (P = 0.056) in the post-operative
CRT group in the present study. These differences may
have affected our results: no significant difference was
seen in the LR rates between the different CRT groups
and only a tendency for delayed LR development was
identified in the pre-operative CRT group.
The major portion of the lymphatic drainage of the
rectum passes along the superior hemorrhoidal arterial
trunk, towards the inferior mesenteric artery. The
pararectal nodes above the level of the middle rectal
valve drain exclusively along the superior hemorrhoidal
lymphatic chain. Below this level, some lymphatics pass
to the lateral rectal pedicle. These lymphatics are asso-
ciated with nodes along the middle hemorrhoidal artery,
obturator fossa, and the hypogastric and common iliac
arteries [6]. In the present study, we demonstrated that
tumor location within the rectum influenced patterns of
DM. Liver recurrence is reportedly the most common
site of distant failure in colorectal cancer, whereas the
present study of rectal cancer alone showed that the
lung was a more common DM site than the liver. A
similar finding was reported by Ding et al., that pulmon-
ary recurrence predominated in LARC patients who
received pre-operative CRT [14]. In their study, tumor
location (≤ 5 cm) was significantly associated with pul-
monary recurrence. Similarly, we showed that metastasis
to para-aortic lymph nodes or the lungs was relatively
more frequent in patients with low-to-mid rectal cancer,
while metastasis to the liver was more common from
upper rectal cancer. Additionally, in the present study,
we showed that DM from low rectal tumors occurred
later than DM from upper-to-mid rectal tumors, and
lung metastasis took a longer time than liver metastasis.
Following initial treatments for patients with LARC, one
of the purposes of post-treatment surveillance is to dis-
cover a recurrence that is potentially curable. When LR
does occur, curative salvage therapy has been of limited
success; curative surgery is possible for only 20–30%
of patients. However, definitive CRT was recently sug-
gested as a potentially curative option for unresectable LR
[15,16]. For oligometastatic status (liver or lung), 5-year
survival of up to 50–60% has been achieved [17,18]. Favor-
able outcomes have also been reported following curative
CRT for isolated para-aortic lymph node metastasis from
colorectal cancer [19]. If recurrence can be detected when
it is limited in site or number and thus resectable or
curable, increased success of salvage therapy can beexpected. The results of the present study, that there are
patterns of failure, including time and sites of recurrences,
will facilitate optimization of follow-up modalities and
schedules. As recurrence rates are lowered through im-
proved treatments, more prolonged follow-up surveillance
may be necessary. Follow-up may need to be individua-
lized, based on initial tumor location within the rectum.
This study has some limitations. First, the primary ob-
jective was not to investigate patterns of failure in a single
arm, but to compare them between two groups managed
with different treatment schemes. The two groups did not
have different follow-up periods, but follow-up was not
sufficiently long to detect late recurrences in some pa-
tients; 13.5% (91/673) of the living patients were followed
for less than 5 years. Second, only the first site of failure
was analyzed. This may underestimate the true incidence
of failures compared with studies including total cumula-
tive failures. In particular, whether LR occurrence in pa-
tients who previously showed DM alone is true LR or
dissemination from the precedent DM is disputable. This
situation was identified in 15 patients in the present study.Conclusions
In conclusion, in this study, we showed that LARC pa-
tients developed similar patterns of failure whether they
received CRT before or after surgery; however, those re-
ceiving pre-operative CRT tended to develop later LR.
The lung was the most common site of DM. Lung metas-
tasis occurred more in patients whose primary tumor was
located in the distal rectum, and it took longer than did
liver metastasis. Further extended follow-up may reveal
patterns of failure more clearly in LARC patients managed
with multimodal treatments. Such information will facili-
tate optimization of follow-up strategies and provision of
successful salvage therapy.
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